Monopar files provisional patent for MNPR-101 radiopharma optimization findings

Monopar Therapeutics

Filed provisional patent 'Antibody Radioisotope Constructs' covering MNPR-101-Zr construct, including radioisotope, linker, and antibody variations.
Patent aims to protect stability and biodistribution properties of MNPR-101-Zr.
MNPR-101-Zr is a zirconium-89 imaging version of Monopar's anti-uPAR antibody for advanced cancers.
Filing strengthens IP for MNPR-101 radiopharma program; Phase 1 dosimetry trial recently initiated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.